Markets

Sorrento Therapeutics Gains Rights For Rapid SARS-CoV-2 Virus Diagnostic Test

(RTTNews) - Sorrento Therapeutics, Inc. (SRNE) has entered into a licensing agreement with Columbia University for the rights to a rapid, one-step diagnostic test that detects SARS-CoV-2 virus within 30 minutes from a sample of saliva. Developed by Zev Williams, and his team at the Columbia University Fertility Center, the COVI-TRACE approach eliminates the need for nasal swabbing.

Under the COVI-TRACE method, a small sample of saliva is collected in a cup and then placed into a tube containing enzymes and reagents. The tube is then placed into a heat block or water bath to keep the sample warm throughout the chemical reaction, which takes 30 minutes or less to provide a colorimetric reading based on detection of the presence of the virus.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SRNE

Latest Markets Videos

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More